Dysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia
Abstract
Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in the substantia nigra, the depletion of striatal dopamine and the presence of Lewy aggregates containing alpha-synuclein. Clinically, there are motor impairments involving cardinal movement symptoms, bradykinesia, resting tremor, muscle rigidity, and postural abnormalities, along with non-motor symptoms such as sleep, behavior and mood disorders. The current treatment for PD focuses on restoring dopaminergic neurotransmission by l-3,4-dihydroxyphenylalanine (levodopa), which loses therapeutic efficacy and induces disabling abnormal involuntary movements known as levodopa-induced dyskinesia (LID) after several years. Evidence indicates that the pathophysiology of both PD and LID disorders is also associated with the dysfunctional activity of the serotonergic (5-HT) neurons that may be responsible for motor and non-motor disturbances. The main population of 5-HT neurons is located in the dorsal raphe nuclei (DRN), which provides extensive innervation to almost the entire neuroaxis and controls multiple functions in the brain. The degeneration of DRN 5-HT neurons occurs in early PD. These neurons can also take exogenous levodopa to transform it into dopamine, which may disturb neuron activity. This review will provide an overview of the underlying mechanisms responsible for 5-HT dysfunction and its clinical relevance in PD and dyskinesia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The motor symptoms of Parkinson's disease may result from decreased dopamine and serotonin levels.
“The motor symptoms of PD may result from decreased dopamine and serotonin levels [41,42].”
From Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson’s Disease (2023) · cites this paper as [42]
Cites
Parallel organization of functionally segregated circuits linking basal ganglia and cortex
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002041 · Cited by 8,527 · see citing works
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · see citing works
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,412 · see citing works
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K. S., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,945 · see citing works
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683 · see citing works
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,456 · see citing works
The Parkinson Pandemic—A Call to Action
Dorsey, E. R., & Bloem, B. R. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3299 · Cited by 1,108 · see citing works
A new era for understanding amyloid structures and disease
Iadanza, M. G., Jackson, M. P., Hewitt, E. W., Ranson, N. A., & Radford, S. E. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0060-8 · Cited by 969 · see citing works
Cummings, J. L., Isaacson, S., Mills, R., Williams, H., Chi‐Burris, K., Corbett, A., Dhall, R., & Ballard, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954 · see citing works
Bendor, J. T., Logan, T. P., & Edwards, R. H. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.004 · Cited by 825 · see citing works
Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease
Obeso, J. A., Rodríguez-Oroz, M. C., Benítez‐Temiño, B., Blesa, F. J., Guridi, J., Marı́n, C., & Rodrı́guez, M. (2008) · Movement Disorders · doi:10.1002/mds.22062 · Cited by 669 · see citing works
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Carta, M., Carlsson, T., Kirik, D., & Björklund, A. (2007) · Brain · doi:10.1093/brain/awm082 · Cited by 637 · see citing works
Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448 · see citing works
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Kish, S. J., Tong, J., Hornykiewicz, O., Rajput, A. H., Chang, L.-J., Guttman, M., & Furukawa, Y. (2007) · Brain · doi:10.1093/brain/awm239 · Cited by 376 · see citing works
Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease
Halliday, G. M., Blumbergs, P. C., Cotton, R. G. H., Blessing, W. W., & Geffen, L. B. (1990) · Brain Research · doi:10.1016/0006-8993(90)90733-r · Cited by 366 · see citing works
Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors
Leo, R. J. (1996) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v57n1002 · Cited by 365 · see citing works
Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction
Pavese, N., Metta, V., Bose, S. K., Chaudhuri, К. R., & Brooks, D. J. (2010) · Brain · doi:10.1093/brain/awq268 · Cited by 335 · see citing works
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324 · see citing works
Tremor in Parkinson’s disease and serotonergic dysfunction
Doder, M., Rabiner, E. A., Turjanski, N., Lees, A. J., & Brooks, D. J. (2003) · Neurology · doi:10.1212/01.wnl.0000031424.51127.2b · Cited by 302 · see citing works
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A. D., Bahr, D., & Friedman, J. H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 293 · see citing works
Maillet, A., Krack, P., Lhommée, E., Météreau, É., Klinger, H., Favre, É., Bars, D. L., Schmitt, E., Bichon, A., Pélissier, P., et al. (2016) · Brain · doi:10.1093/brain/aww162 · Cited by 282 · see citing works
Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.35 · Cited by 266 · see citing works
Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., & Cenci, M. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06556.x · Cited by 264 · see citing works
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
Ottosson, D. R., Parent, M., O’Sullivan, S. S., Doveró, S., Lees, A. J., Bézard, E., Descarries, L., & Cenci, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.22097 · Cited by 262 · see citing works
Goetz, C. G., Damier, P., Hicking, C., LASKA, E. M., Müller, T. H., Olanow, C. W., Rascol, O., & Russ, H. (2006) · Movement Disorders · doi:10.1002/mds.21226 · Cited by 260 · see citing works
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients
Politis, M., Wu, K., Loane, C., Brooks, D. J., Kiferle, L., Turkheimer, F., Bain, P. G., Molloy, S., & Piccini, P. P. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71640 · Cited by 245 · see citing works
Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study
Politis, M., Wu, K., Loane, C., Kiferle, L., Molloy, S., Brooks, D. J., & Piccini, P. P. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.028 · Cited by 242 · see citing works
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
Bibbiani, F., Oh, J. D., & Chase, T. N. (2001) · Neurology · doi:10.1212/wnl.57.10.1829 · Cited by 241 · see citing works
Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review
Petrou, M., Dwamena, B. A., Foerster, B. R., MacEachern, M., Bohnen, N. I., Müller, M. L. T. M., Albin, R. L., & Frey, K. A. (2015) · Movement Disorders · doi:10.1002/mds.26191 · Cited by 222 · see citing works
Dekundy, A., Lundblad, M., Danysz, W., & Cenci, M. A. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.01.013 · Cited by 219 · see citing works
Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.
Qamhawi, Z., Towey, D., Shah, B., Pagano, G., Seibyl, J., Marek, K., Borghammer, P., Brooks, D., & Pavese, N. (2015) · Brain : a journal of neurology · doi:10.1093/brain/awv215 · Cited by 216 · see citing works
Buspirone in Levodopa-Induced Dyskinesias
Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N., & Meco, G. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199402000-00008 · Cited by 181 · see citing works
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
Svenningsson, P., Rosenblad, C., Arvidsson, K. A. E., Wictorin, K., Keywood, C., Shankar, B., Lowe, D. A., Björklund, A., & Widner, H. (2015) · Brain · doi:10.1093/brain/awu409 · Cited by 162 · see citing works
Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease
Fox, S. H. (2013) · Drugs · doi:10.1007/s40265-013-0105-4 · Cited by 148 · see citing works
Jaunarajs, K. L. E., Gupta, V., Alam, S., Park, J. Y., & Bishop, C. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.05.002 · Cited by 144 · see citing works
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia
Bézard, E., Tronci, E., Pioli, E. Y., Li, Q., Porras, G., Björklund, A., & Carta, M. (2013) · Movement Disorders · doi:10.1002/mds.25366 · Cited by 136 · see citing works
Alarcón-Arís, D., Recasens, A., Galofré, M., Carballo‐Carbajal, I., Zacchi, N., Ruiz‐Bronchal, E., Pavia-Collado, R., Chica, R., Ferrés‐Coy, A., Santos, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.015 · Cited by 133 · see citing works
Politis, M., Wu, K., Loane, C., Quinn, N. P., Brooks, D. J., Oertel, W. H., Björklund, A., Lindvall, O., & Piccini, P. P. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003391 · Cited by 129 · see citing works
Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease
Ye, Z., Altena, E., Nombela, C., Housden, C. R., Maxwell, H., Rittman, T., Huddleston, C., Rae, C. L., Regenthal, R., Sahakian, B. J., et al. (2014) · Brain · doi:10.1093/brain/awu032 · Cited by 118 · see citing works
Zhang, X., Andrén, P. E., Greengard, P., & Svenningsson, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711839105 · Cited by 117 · see citing works
Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD
Loane, C., Wu, K., Bain, P. G., Brooks, D. J., Piccini, P. P., & Politis, M. (2013) · Neurology · doi:10.1212/wnl.0b013e318292a31d · Cited by 115 · see citing works
Calon, F., Morissette, M., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Paolo, T. D. (2002) · Movement Disorders · doi:10.1002/mds.10343 · Cited by 110 · see citing works
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.007 · Cited by 102 · see citing works
Miguélez, C., Morera-Herreras, T., Torrecilla, M., Ruíz-Ortega, J., & Ugedo, L. (2014) · Front. Neural Circuits · doi:10.3389/fncir.2014.00021 · Cited by 101 · see citing works
Self-citationGrégoire, L., Samadi, P., Graham, J., Bédard, P. J., Bartoszyk, G. D., & Paolo, T. D. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.11.001 · Cited by 97 · see citing works
Zuo, L.-J., Yu, S., Hu, Y., Wang, F., Piao, Y., Lian, T., Yu, Q.-J., Wang, R., Li, L., Guo, P., et al. (2016) · Scientific Reports · doi:10.1038/s41598-016-0018-z · Cited by 93 · see citing works
Modulation of the trafficking of the human serotonin transporter by human alpha‐synuclein
Wersinger, C., Rusnak, M., & Sidhu, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04900.x · Cited by 93 · see citing works
Shannak, K. S., Rajput, A. H., Rozdilsky, B., et al. (1994) · Brain Research · doi:10.1016/0006-8993(94)91761-2 · Cited by 91 · see citing works
Serotonergic dysregulation is linked to sleep problems in Parkinson's disease
Wilson, H., Giordano, B., Turkheimer, F., Chaudhuri, К. R., & Politis, M. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.03.001 · Cited by 91 · see citing works
Kohl, Z., Abdallah, N. B. B., Vogelgsang, J., Tischer, L., Deusser, J., Amato, D., Anderson, S., Müller, C., Riess, O., Masliah, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.10.021 · Cited by 89 · see citing works
Dupre, K. B., Jaunarajs, K. L. E., Negron, G. E., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.05.005 · Cited by 83 · see citing works
Tong, Q., Zhang, L., Yuan, Y., Jiang, S., Zhang, R., Xu, Q., Ding, J., Li, D., Zhou, X., & Zhang, K. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.016 · Cited by 81 · see citing works
Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders
Kovács, G. G., Klöppel, S., Fischer, I., Dorner, S., Lindeck‐Pozza, E., Birner, P., Bötefür, I. C., Pilz, P. K. D., Volk, B., & Budka, H. (2003) · Neuroreport · doi:10.1097/00001756-200301200-00014 · Cited by 81 · see citing works
Takahashi, M., Tabu, H., Ozaki, A., Hamano, T., Takeshima, T., & for the REBORN study group (2018) · Internal Medicine · doi:10.2169/internalmedicine.1359-18 · Cited by 77 · see citing works
Bishop, C., George, J. A., Buchta, W. C., Goldenberg, A. A., Mohamed, M., Dickinson, S. O., Eissa, S., & Jaunarajs, K. L. E. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08202.x · Cited by 75 · see citing works
Buspirone in the treatment of levodopa induced dyskinesias.
Kleedorfer, B., Lees, A. J., & Stern, G. M. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.4.376-a · Cited by 75 · see citing works
Clues to how alpha‐synuclein damages neurons in Parkinson's disease
Sulzer, D. L. (2010) · Movement Disorders · doi:10.1002/mds.22639 · Cited by 68 · see citing works
L-Dopa and Brain Serotonin System Dysfunction
Stansley, B. J., & Yamamoto, B. K. (2015) · Toxics · doi:10.3390/toxics3010075 · Cited by 64 · see citing works
Serotonin, β‐amyloid, and cognition in Parkinson disease
Kotagal, V., Spino, C., Bohnen, N. I., Koeppe, R., & Albin, R. L. (2018) · Annals of Neurology · doi:10.1002/ana.25236 · Cited by 64 · see citing works
Dystrophic serotonergic axons in neurodegenerative diseases
Azmitia, E. C., & Nixon, R. A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.060 · Cited by 63 · see citing works
Huang, X., Yang, J., Yang, S., Cao, S., Qin, D., Zhou, Y., Li, X., Ye, Y., & Wu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22170 · Cited by 60 · see citing works
Caretti, V., Stoffers, D., Winogrodzka, A., Isaias, I. U., Costantino, G., Pezzoli, G., Ferrarese, C., Antonini, A., Wolters, E. C., & Booij, J. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-007-0015-2 · Cited by 59 · see citing works
Ghiglieri, V., Mineo, D., Vannelli, A., Cacace, F., Mancini, M., Pendolino, V., Napolitano, F., di Maio, A., Mellone, M., Stanic, J., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.11.022 · Cited by 58 · see citing works
Paolone, G., Brugnoli, A., Arcuri, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26326 · Cited by 56 · see citing works
Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias
Riahi, G., Morissette, M., Parent, M., & Paolo, T. D. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07675.x · Cited by 51 · see citing works
Fidalgo, C., Ko, W. K. D., Tronci, E., Li, Q., Stancampiano, R., Chuan, Q., Bézard, E., & Carta, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.04.027 · Cited by 50 · see citing works
Serotonin transporter binding and anxiety symptoms in Parkinson’s disease
Joling, M., van den Heuvel, O. A., Berendse, H. W., Booij, J., & Vriend, C. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316193 · Cited by 50 · see citing works
Lim, J., Bang, Y., Choi, J.-H., Han, A., Kwon, M., Liu, K., & Choi, H. J. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.4051-15.2017 · Cited by 50 · see citing works
Neonatal fluoxetine exposure alters motor performances of adolescent rats
Lee, L., & Lee, L. J. (2011) · Developmental Neurobiology · doi:10.1002/dneu.20942 · Cited by 48 · see citing works
Dopamine release from serotonergic nerve fibers is reduced in L ‐DOPA‐induced dyskinesia
Nevalainen, N., af Bjerkén, S., Lundblad, M., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07292.x · Cited by 47 · see citing works
Serotonergic mediated body mass index changes in Parkinson's disease
Politis, M., Loane, C., Wu, K., Brooks, D. J., & Piccini, P. P. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.009 · Cited by 45 · see citing works
Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys
Gagnon, D., Grégoire, L., Paolo, T. D., & Parent, M. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1125-5 · Cited by 44 · see citing works
Chronic l-Dopa Decreases Serotonin Neurons in a Subregion of the Dorsal Raphe Nucleus
Stansley, B. J., & Yamamoto, B. K. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218966 · Cited by 44 · see citing works
Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders
Tatara, A., Shimizu, S., Shin, N., Sato, M., Sugiuchi, T., Imaki, J., & Ohno, Y. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.008 · Cited by 43 · see citing works
Hamadjida, A., Nuara, S. G., Bédard, D., Gaudette, F., Beaudry, F., Gourdon, J. C., & Huot, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.038 · Cited by 43 · see citing works
Aristieta, A., Ruíz-Ortega, J. Á., Miguélez, C., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.02.003 · Cited by 41 · see citing works
Self-citationThe Role of the Subthalamic Nucleus in L-DOPA Induced Dyskinesia in 6-Hydroxydopamine Lesioned Rats
Aristieta, A., Azkona, G., Sagarduy, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042652 · Cited by 40 · see citing works
Self-citationPrinz, A., Selesnew, L.-M., Liss, B., Roeper, J., & Carlsson, T. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.06.015 · Cited by 38 · see citing works
Miguélez, C., Navailles, S., Deurwaerdère, P. D., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13447 · Cited by 30 · see citing works
Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease
Huot, P., Johnston, T. H., Visanji, N. P., Darr, T., Pires, D., Hazrati, L., Brotchie, J. M., & Fox, S. H. (2012) · Movement Disorders · doi:10.1002/mds.24964 · Cited by 29 · see citing works
Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats
Conti, M. M., Meadows, S. M., Melikhov-Sosin, M., Lindenbach, D., Hallmark, J., Werner, D. F., & Bishop, C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.025 · Cited by 29 · see citing works
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Pagano, G., Yousaf, T., & Politis, M. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0794-2 · Cited by 28 · see citing works
Evidence for Sprouting of Dopamine and Serotonin Axons in the Pallidum of Parkinsonian Monkeys
Gagnon, D., Eid, L., Coudé, D., Whissel, C., Paolo, T. D., Parent, A., & Parent, M. (2018) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2018.00038 · Cited by 28 · see citing works
Partial regulation of serotonin transporter function by γ-synuclein
Wersinger, C., & Sidhu, A. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.02.033 · Cited by 27 · see citing works
Azkona, G., Sagarduy, A., Aristieta, A., Vázquez, N., Zubillaga, V., Ruíz-Ortega, J. Á., Pérez‐Navarro, E., Ugedo, L., & Sánchez‐Pernaute, R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.024 · Cited by 27 · see citing works
Self-citationThe serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein
Jinsmaa, Y., Cooney, A. M., Sullivan, P., et al. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.01.064 · Cited by 26 · see citing works
Gerlach, M., Bartoszyk, G. D., Riederer, P. F., et al. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0571-8 · Cited by 25 · see citing works
Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration
Aristieta, A., Morera‐Herreras, T., Ruíz-Ortega, J. Á., Miguélez, C., Vidaurrazaga, I., Arrúe, A., Zumárraga, M., & Ugedo, L. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3333-0 · Cited by 24 · see citing works
Self-citationl-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats
Miguélez, C., Berrocoso, E., Micó, J. A., & Ugedo, L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.016 · Cited by 23 · see citing works
Self-citationMiguélez, C., Benazzouz, A., Ugedo, L., & Deurwaerdère, P. D. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00274 · Cited by 22 · see citing works
Self-citationFrouni, I., Kwan, C., Bédard, D., Belliveau, S., Bourgeois-Cayer, É., Gaudette, F., Beaudry, F., Hamadjida, A., & Huot, P. (2018) · Experimental Brain Research · doi:10.1007/s00221-018-5390-4 · Cited by 22 · see citing works
Inden, M., Abe, M., Minamino, H., Takata, K., Yoshimoto, K., Tooyama, I., & Kitamura, Y. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.12003fp · Cited by 21 · see citing works
Behavioral impairments and serotonin reductions in rats after chronic L-dopa
Stansley, B. J., & Yamamoto, B. K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3980-4 · Cited by 20 · see citing works
Effect of chronic l-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain
Riahi, G., Morissette, M., Lévesque, D., et al. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.009 · Cited by 20 · see citing works
Beaudoin‐Gobert, M., Météreau, É., Duperrier, S., Thobois, S., Tremblay, L., & Sgambato, V. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.08.016 · Cited by 19 · see citing works
Sagarduy, A., Llorente, J., Miguélez, C., Morera‐Herreras, T., Ruíz-Ortega, J. Á., & Ugedo, L. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.12.005 · Cited by 18 · see citing works
Self-citationWan, O. W., Shin, E., Mattsson, B., Caudal, D., Svenningsson, P., & Björklund, A. (2016) · Scientific Reports · doi:10.1038/srep26285 · Cited by 17 · see citing works
Dallé, E., Daniels, W. M. U., & Mabandla, M. V. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.05.014 · Cited by 17 · see citing works
Beucke, J. C., Plotkin, M., Winter, C., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03274.x · Cited by 15 · see citing works
Persistent dystonia induced by fluoxetine
Bilen, Ş., Saka, M., Ak, F., et al. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01747.x · Cited by 12 · see citing works
Gerlach, M., Beck, J., Riederer, P. F., et al. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0570-9 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Guo, T.-T., Zhang, Z., Sun, Y., Zhu, R.-Y., Wang, F.-X., Ma, L.-J., Jiang, L., & Liu, H.-D. (2023) · Nutrients · doi:10.3390/nu15040930 · Cited by 82 · see citing works
Khan, A. F., Adewale, Q., Lin, S.-J., Baumeister, T. R., Zeighami, Y., Carbonell, F., Palomero-Gallagher, N., & Iturria-Medina, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41677-w · Cited by 28 · see citing works
- Authors
- Vegas-Suarez, S., Paredes-Rodriguez, E., Aristieta, A., Lafuente, J. V., Miguelez, C., & Ugedo, L.
- Affiliations
- University of the Basque Country (ES)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Ugedo, Luisa
- Venue
- International Review of Neurobiology
- Publisher
- Elsevier
- Published
- 2019
- Volume
- 146
- Pages
- 259-279
- ISSN
- 0074-7742 (ISSN-L)
- OpenAlex
- W2963147943
- Cited by
- 26
- References
- 101
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 4 · 2019: 1
- FWCI
- 10.10
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- Locations
- International review of neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agencia Estatal de Investigación
- Eusko Jaurlaritza
- Ministerio de Economía y Competitividad (SAF2016-77758-R)
- Euskal Herriko Unibertsitatea
- Universitat Politècnica de València
- European Regional Development Fund (IT-901/16, T747-13)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- Parkinson's disease, levodopa-induced dyskinesia, serotonergic neurons, dorsal raphe nucleus, serotonin dysfunction, dopaminergic neuron loss, levodopa metabolism, non-motor symptoms, motor symptoms, Lewy bodies, alpha-synuclein
- MeSH terms
- Animals, Brain, Dyskinesia, Drug-Induced, Humans, Levodopa, Models, Neurological, Parkinson Disease, Serotonergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
